It’s Been a Decade of AI in the Drug Discovery Race. What’s Next?

<!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"> <title>It’s Been a Decade of AI in the Drug Discovery Race. What’s Next?</title> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <link rel="canonical" href="https://www.biopharmatrend.com/ai-drug-discovery-pipeline/" />  <script async src="https://www.googletagmanager.com/gtag/js?id=G-YK7FCK71TD"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-YK7FCK71TD'); </script> <meta name="description" content="Discover the latest trends and advancements in AI drug discovery, including innovative technologies, emerging startups, and key players transforming pharmaceutical research and development through artificial intelligence." />  <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:title" content="It’s Been a Decade of AI in the Drug Discovery Race. What’s Next?"> <meta name="twitter:description" content="Discover the latest trends and advancements in AI drug discovery, including innovative technologies, emerging startups, and key players transforming pharmaceutical research and development through artificial intelligence."> <meta name="twitter:image" content="https://www.biopharmatrend.com/static/img/ai_pipelines_cover_soc.d986a3786f9d.jpg">  <meta property="og:type" content="article" /> <meta property="og:url" content="https://www.biopharmatrend.com/ai-drug-discovery-pipeline/" /> <meta property="og:title" content="It’s Been a Decade of AI in the Drug Discovery Race. What’s Next?" /> <meta property="og:description" content="Discover the latest trends and advancements in AI drug discovery, including innovative technologies, emerging startups, and key players transforming pharmaceutical research and development through artificial intelligence." /> <meta property="og:image" content="https://www.biopharmatrend.com/static/img/ai_pipelines_cover_soc.d986a3786f9d.jpg"> <link rel="shortcut icon" href="/static/favicon.ab1145f4d518.ico" /> <link rel="stylesheet" type="text/css" href="/static/css/main.6dead4e2266d.css" /> <link rel="stylesheet" type="text/css" href="/static/css/marketplace.9b06f2a8dc19.css" /> <style> html body { background-color: white; } body #main-content { margin-top: 0; } #pipelines-article { color: hsl(120, 0%, 30%); position: relative; } #pipelines-article::before { content: ""; display: block; position: absolute; top: 0; left: calc(50% - 50vw); z-index: -1; width: 100vw; height: 100vh; background-color: forestgreen; background-image: url("/static/img/ai_pipelines_abstract_bg3.df722b903067.webp"); background-size: cover; background-repeat: no-repeat; background-position: center; } #pipelines-article .overlay { display: block; position: absolute; top: 0; left: calc(50% - 50vw); z-index: -1; width: 100vw; height: 100vh; background-color: #206020; opacity: 0.6; } #pipelines-article > header { color: hsl(40, 43%, 96%); font-size: 18px; text-shadow: 0 0 16px #105010; padding: 3em 0; margin-left: 3em; } #pipelines-article > header a { color: hsl(40, 43%, 86%); } #pipelines-article .author-linkein-icon { width: 1em; vertical-align: baseline; background-color: white; border-radius: 4px; } #pipelines-article header h1 { font-size: min(3em, 6vw); line-height: 1.25; color: hsl(120, 0%, 100%); margin: 0; } #pipelines-article section { margin-bottom: 3em; padding-left: 3em; font-size: 18px; line-height: 1.5; } #pipelines-article > header, #pipelines-article section p, #pipelines-article section h2, #pipelines-article section h3, #pipelines-article section h4 { max-width: 45rem; } #pipelines-article h1#image-style { font-family: Impact, sans-serif; font-size: 2em; margin: 0.5em 0; color: hsl(120, 0%, 35%); font-weight: normal; } .table-container { width: 100%; overflow-x: auto; margin-bottom: 3rem; } #pipelines-table { font-family: sans-serif; line-height: 1.2; border-collapse: collapse; font-size: 14px; min-width: 100%; } #pipelines-table th { font-family: Impact, sans-serif; color: hsl(120, 60%, 35%); font-weight: normal; padding: 0.25em 0.5em 0.5em; text-align: center; vertical-align: middle; background-color: white; } #pipelines-table td { padding: 0.25em 0.5em; text-align: center; vertical-align: middle; } #pipelines-table .switcher { display: inline-block; padding: 0.5em 2em; border-radius: 0.25em; font-weight: bold; background: white; border: 1px solid hsl(10, 60%, 90%); color: hsl(10, 40%, 40%); } #pipelines-table.pipelines-collapse .switcher { background: hsl(10, 30%, 95%); border-color: hsl(10, 60%, 80%); color: hsl(10, 50%, 30%); } #pipelines-table .switcher:hover { color: hsl(10, 30%, 50%); } #pipelines-table .switcher::before { content: "Hide additional info"; display: inline-block; } #pipelines-table.pipelines-collapse .switcher::before { content: "Expand additional info"; } .col-collapse { transition: width 1s, height 0.5s; } #pipelines-table.pipelines-collapse .col-collapse { white-space: nowrap; text-overflow: clip; overflow: hidden; max-width: 0; padding-right: 0px; padding-left: 2px; border-left: 1px dashed hsl(120, 0%, 75%); } .pipelines-collapse th.col-collapse { width: 0px !important; } #pipelines-table tr { border-bottom: 1px solid hsl(120, 0%, 90%); } #pipelines-table tr.divide-top { border-top: 3px solid hsl(200, 10%, 80%); } .company-cell { background: hsl(200, 0%, 60%); color: white; position: relative; } .company-cell p { transform: translate(-50%, 0%) rotate(-90deg); font-weight: bold; letter-spacing: 2px; margin: 0; position: absolute; top: calc(50% - 0.5em); left: 2em; white-space: nowrap; } .company-cell a, .company-cell a:active { color: white; } #pipelines-table .col-year { border-left: 1px dashed hsl(120, 30%, 85%); padding: 0.25em 0; } #pipelines-table.pipelines-collapse .col-year { /* width: 12%; */ } .pip { display: inline-block; width: 100%; font-size: 12px; padding: 0.5em 0; line-height: 1; position: relative; white-space: nowrap; text-overflow: clip; } .pip::before { content: ""; position: absolute; top: 0; left: 0; height: 0; width: 0; border-width: 1em 0 1em 0.5em; border-style: solid; border-color: transparent transparent transparent white; } .pip::after { content: ""; position: absolute; top: 0; right: 0; height: 0; width: 0; border-width: 1em 0 1em 0.5em; border-style: solid; border-color: white transparent white transparent; } .pip-discovery { background-image: linear-gradient(hsl(200, 60%, 85%), hsl(200, 60%, 95%), hsl(200, 60%, 85%)); color: hsl(200, 20%, 60%); } .pip-preclinical { background-image: linear-gradient(hsl(160, 60%, 75%), hsl(160, 60%, 90%), hsl(160, 60%, 75%)); color: hsl(160, 40%, 40%); } .pip-phase1 { background-image: linear-gradient(hsl(130, 60%, 60%), hsl(130, 60%, 70%), hsl(130, 60%, 60%)); color: hsl(130, 100%, 100%); } .pip-phase2 { background-image: linear-gradient(hsl(120, 60%, 40%), hsl(120, 60%, 55%), hsl(120, 60%, 40%)); color: hsl(120, 0%, 100%); } .pip-phase3 { background-image: linear-gradient(hsl(110, 60%, 30%), hsl(110, 60%, 45%), hsl(110, 60%, 30%)); color: hsl(110, 0%, 100%); } .pip.pip-failed { box-shadow: 0 0 0px 3px hsl(10, 100%, 60%) inset; color: hsl(10, 100%, 95%); width: 60%; margin-right: 40%; text-align: left; padding-left: 0.5em; } .pip.pip-failed::after { content: "\2573"; border: none; height: auto; width: auto; padding: 0.5em 0.5em; color: hsl(10, 100%, 50%); font-weight: bold; right: -2em; background: white; } .pip.pip-hold { opacity: 0.8; box-shadow: 0 0 3px 1px hsl(10, 0%, 80%) inset; color: hsl(10, 0%, 65%); width: 75%; margin-right: 25%; text-align: left; padding-left: 0.5em; } .pip.pip-hold::after { content: "\220E"; border: none; height: auto; width: auto; padding: 0.5em 0.25em; right: -1.25em; background: white; } /* text blocks */ .platform-block { font-size: 1.25em; line-height: 1.5; text-align: left; background-color: hsl(120, 0%, 90%); } .platform-block.platform-block-2 { background-color: white; } .platform-block .api-form { border-bottom: none; margin: 0; padding: 0; } .platform-block .api-form .btn-default { background-color: rgba(255,255,255,0.5); width: 100%; } .platform-block .api-form .btn-default:hover { background-color: rgba(255,255,255,1); } .platform-block #captcha { margin-left: 0; } .platform-block .api-form input, .platform-block .api-form textarea { width: 100%; background: rgba(255, 255, 255, 0.7); } .platform-block h2 { font-size: min(2.5em, 5vw); margin: 0.5em 0 1.5em; max-width: 18em; line-height: 1.25; } .platform-block h3 { font-size: min(2em, 4vw); margin-bottom: 1.5em; } #article-sign { text-align: center; font-size: min(2em, 4vw); color: rgba(34, 130, 34, 0.5); letter-spacing: 3px; font-weight: bold; margin-top: 2em; } @media screen and (max-width: 40em) { .platform-block { font-size: 1rem; } #pipelines-article section { font-size: 1rem; padding-left: 1.25em; } #pipelines-article > header { font-size: 1rem; margin-left: 1.25em; padding-right: 1.25em; } } @media screen and (max-width: 68em) { } /* financial table */ #finance-table { font-family: sans-serif; line-height: 1.2; border-collapse: collapse; font-size: 14px; min-width: 100%; } #finance-table tr { border-bottom: 1px solid hsl(120, 0%, 90%); } #finance-table tr.divide-top { border-top: 3px solid hsl(200, 10%, 80%); } #finance-table th { color: hsl(120, 60%, 35%); padding: 0.25em 0.5em 0.5em; text-align: center; vertical-align: middle; background-color: white; } #finance-table td { padding: 0.25em 0.5em; text-align: center; vertical-align: middle; } #finance-table td:first-child { text-align: left; } #finance-table th[colspan], #finance-table td[colspan] { border-left: 1px solid hsl(120, 0%, 70%); border-right: 1px solid hsl(120, 0%, 70%); } #finance-table tr td:nth-child(3n-2) { border-right: 1px solid hsl(120, 0%, 70%); } #finance-summary { font-family: sans-serif; line-height: 1.2; border-collapse: collapse; font-size: 14px; min-width: 100%; } #finance-summary tr { border-bottom: 1px solid hsl(120, 0%, 90%); } #finance-summary th { color: hsl(120, 60%, 35%); padding: 0.25em 0.5em 0.5em; text-align: center; vertical-align: middle; background-color: white; border: 1px solid hsl(120, 0%, 90%); border-bottom-width: 2px; } #finance-summary td { padding: 0.25em 0.5em; text-align: center; vertical-align: top; border-left: 1px solid hsl(120, 0%, 90%); border-right: 1px solid hsl(120, 0%, 90%); } .chart-bar { display: block; margin-top: 0.5em; margin-bottom: 0.5em; height: 0.5em; background: hsl(120, 20%, 80%); } .bar-yellow { background-color: hsl(55, 80%, 35%); } .bar-blue { background-color: hsl(200, 100%, 30%); } .bar-red { background-color: hsl(350, 100%, 35%); margin-left: auto; margin-right: 0; } .bar-green { background-color: hsl(120, 100%, 30%); } .price-change-up::before { content: "\21D1 "; color: hsl(120, 100%, 40%); display: inline-block; margin-right: 0.25em; } .price-change-down::before { content: "\21D3 "; color: hsl(0, 100%, 40%); display: inline-block; margin-right: 0.25em; } </style> </head> <body> <div id="main-preheader"> <div class="container block-preheader"> <div id="logo-top"> <a href="/"><b>BioPharmaTrend</b></a>  </div> <div class="burger-container"> <div class="burger-button-container"> <button type="button" class="burger-button" onclick="document.documentElement.classList.toggle('blockfix');this.parentElement.parentElement.classList.toggle('active');"> <div class="burger-line burger-line-1"></div> <div class="burger-line burger-line-2"></div> <div class="burger-line burger-line-3"></div> </button> </div>  <div id="main-search-menu"> <div class="top-search"> <form action="/search/" class="top-search-form"> <button type="submit" class="btn btn-default"><i class="glyphicon glyphicon-search"></i></button> <input type="text" name="q" value="" size="10" class="form-control form-control-inline" required="" placeholder="e.g. 'quantum tech' or 'stem cell'"> <input type="hidden" name="section" value="insights"> </form> <span class="top-search-switcher button" onclick="this.parentElement.classList.toggle('active')"> <span class="glyphicon glyphicon-search"></span> <span class="glyphicon glyphicon-remove"></span> </span> </div> <span class="top-search-switcher button"> <span class="glyphicon glyphicon-search"></span> </span> </div>  <nav id="main-menu"> <div class="mobile-menu-item"> <a class="top-menu-link mobile-menu-item-title" href="/section/news/"><b>Latest News</b></a> </div> <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">All Topics <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu"> <li><a class="top-menu-link" href="/topic/bioeconomy-society/">Bioeconomy & Society</a></li> <li><a class="top-menu-link" href="/topic/ai-digital/">AI & Digital</a></li> <li><a class="top-menu-link" href="/topic/startups/">Startups & Deals</a></li> <li><a class="top-menu-link" href="/topic/neurotech/">NeuroTech</a></li> <li><a class="top-menu-link" href="/topic/clinical-trials/">Clinical Trials</a></li> <li><a class="top-menu-link" href="/topic/synbio/">Biotech</a></li> <li><a class="top-menu-link" href="/topic/tools-methods/">Tools & Methods</a></li> <li><a class="top-menu-link" href="/topic/healthtech/">HealthTech</a></li> <li><a class="top-menu-link" href="/topic/aging-research/">Aging & Longevity</a></li> <li><a class="top-menu-link" href="/topic/contract-research/">Contract Research</a></li> <div class="sub-menu-margin"></div>  <li><a class="top-menu-link" href="/section/latest/">Latest insights</a></li> <li><a class="top-menu-link" href="/premium-content/">Premium Content</a></li> <div class="sub-menu-margin" style="border-bottom: 1px solid limegreen;"></div> <li><a class="top-menu-link" href="/knowledge-center/">Knowledge Center</a></li> </ul> </div> </div> <div class="mobile-menu-item"> <a class="top-menu-link mobile-menu-item-title" href="/section/interviews/"><b>Interviews</b></a> </div>  <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">Companies <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu">  <li><a class="top-menu-link" href="/m/marketplace/">Company Directory</a></li> <li><a class="top-menu-link" href="/section/interviews/">Interviews with Thought Leaders</a></li> <li><a class="top-menu-link" href="/section/case-studies/">Sponsored Case Studies</a></li> <li><a class="top-menu-link" href="/m/editor-tool/">Create Company Profile</a></li> </ul> </div> </div> <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">More <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu"> <li><a class="top-menu-link" href="/about/">About Us</a></li> <li><a class="top-menu-link" href="/about/team/">Our Team</a></li> <li><a class="top-menu-link" href="/about/advisory-board/">Advisory Board</a></li> <li><a class="top-menu-link" href="/about/press-citations/">Citations and Press Coverage</a></li> <li><a class="top-menu-link" href="/events/">Partner Events Calendar</a></li> <li><a class="top-menu-link" href="/advertising-media-kit/">Advertise with Us</a></li> <li><a class="top-menu-link" href="/contributor/">Write for Us</a></li> </ul> </div> </div> </nav> </div> <div id="main-user-actions">  <div class="mobile-menu-item"> <a href="/membership/" class="button-subscribe top-menu-link">Subscribe</a> </div>  <div class="mobile-menu-item last"> <a href="#" class="mobile-menu-item-title" rel="nofollow" title="Login/Join" onclick="document.getElementById('login-popup').classList.toggle('hidden')"> <span class="glyphicon glyphicon-log-in"></span> <span class="mobile-hide-m">Login/Join</span> </a> </div> </div> </div> </div> <div id="main-preheader-margin"></div> <div id="sencondary-menu-block"> <div class="container clearfix"> <nav> <ul class="text-center"> <li><a href="/topic/ai-digital/">AI & Digital</a></li> <li><a href="/topic/startups/">Startups & Deals</a></li> <li><a href="/topic/neurotech/">NeuroTech</a></li> <li><a href="/topic/clinical-trials/">Clinical Trials</a></li> <li><a href="/topic/synbio/">Biotech</a></li> <li><a href="/topic/tools-methods/">Tools & Methods</a></li> </ul> </nav> </div> </div>  <div id="main-content" class="container"> <article id="pipelines-article"> <div class="overlay"></div> <header> <h1>It’s Been a Decade of AI in the Drug Discovery Race. What’s Next?</h1> <hr style="margin: 3em 0; border-top-width: 2px;"> <div> by <a href="/contributor/9/">Andrii Buvailo</a> <a href="https://www.linkedin.com/in/andriibuvailo/" rel="nofollow" target="_blank"> <img src="/static/img/linkedin_icon_50x50.71dcf83d1029.png" class="author-linkein-icon"> </a> <span style="vertical-align: middle"> | </span> <span class="glyphicon glyphicon-calendar"></span> <time>Apr. 3, 2024</time> </div> </header> <section class="well"> <p>The year 2012 is often regarded as the beginning of the deep learning revolution. </p> <p>That year, Alexnet, the deep learning model proposed in the research paper Imagenet Classification with Deep Convolutional Neural Network by Alex Krizhevsky and his colleagues, <a rel="nofollow" target="_blank" href="https://www.analyticsvidhya.com/blog/2021/03/introduction-to-the-architecture-of-alexnet/#:~:text=Alexnet%20won%20the%20Imagenet%20large,Alex%20Krizhevsky%20and%20his%20colleagues.">won the large-scale visual recognition challenge ImageNet</a> -- completely dominating over other machine learning competitors. </p> <p>Another famous event of that year was <a rel="nofollow" target="_blank" href="https://www.wired.com/2012/06/google-x-neural-network/">spontaneous identification of a cat</a> by another deep neural network -- in millions of random YouTube videos. </p> <p>Scientists at Google's mysterious X lab built a neural network of 16,000 computer processors with one billion connections, and it was never told to look for cats, nor was it told what a cat was. Artificial intelligence learned that by itself and flagged the pattern of pixels corresponding to a cat’s face. </p> <p>While the concept of deep learning was known since the 1960s, the technology only started manifesting itself as a practically viable thing in the 2010s, mainly due to sufficient progress in computational power allowing it to train such complex models. </p> <p>Additionally, 2000-2010s were marked by the increasing availability of big datasets for training purposes, such as ImageNet, and the rise of computational infrastructure, like <a rel="nofollow" target="_blank" href="https://cloudcomputing521.wordpress.com/2017/05/01/history-of-cloud-computing/">Elastic Compute Cloud</a> by Amazon -- other important drivers of the deep learning revolution which started unfolding in 2010-2012. </p> <p> </p> <h2>Historical trajectory of AI in drug discovery</h2> <p>It is no wonder then, that more than 80% of more than 500 AI-augmented drug discovery and development startups and scaleups recorded in BiopharmaTrend database <a target="_blank" href="https://www.biopharmatrend.com/our-products/ai-report/">“The State of AI in the Biopharma Industry”</a> were founded around 2012 and later, around the time deep learning became a major trend. </p> <p> </p> <h3>2012 </h3> <p>Some of the early AI companies, founded in 2012, included <a target="_blank" href="https://www.biopharmatrend.com/m/company/atomwise/">Atomwise</a> (structure based small molecule screening), <a target="_blank" href="https://www.biopharmatrend.com/m/company/exscientia/">Exscientia</a> (target discovery and small molecule design), <a target="_blank" href="https://www.biopharmatrend.com/m/company/abcellera-biologics/">AbCellera</a> (genomics-driven antibody design), and <a target="_blank" href="https://www.biopharmatrend.com/m/company/flatiron-health/">Flatiron Health</a> (a clinical data integrator and analytical powerhouse for clinical research in oncology). </p> <p> </p> <h3>2013</h3> <p>A year later, other notable AI-driven players emerged, including <a target="_blank" href="https://www.biopharmatrend.com/m/company/benevolentai/">BenevolentAI</a>, <a target="_blank" href="https://www.biopharmatrend.com/m/company/cyclica/">Cyclica</a>, and <a target="_blank" href="https://www.biopharmatrend.com/m/company/recursion-pharmaceuticals/">Recursion Pharmaceuticals</a> -- in the small molecule drug discovery space, and <a target="_blank" href="https://www.biopharmatrend.com/m/company/zymergen/">Zymergen</a> in biotech.</p> <p> </p> <h3>2014</h3> <p>But the progress in the artificial intelligence space accelerated, and the year 2014 saw another major milestone, later called by Yann LeCun, Facebook's chief AI scientist at that time, “the coolest idea in deep learning in the last 20 years.”  </p> <p>In June 2014, Ian Goodfellow <a rel="nofollow" target="_blank" href="https://arxiv.org/abs/1406.2661">published a seminal paper</a> introducing Generative Adversarial Networks (GANs). Not only did this breakthrough concept transform the area of generative AI, but it also won his inventor a place in history as <a rel="nofollow" target="_blank" href="https://www.technologyreview.com/2018/02/21/145289/the-ganfather-the-man-whos-given-machines-the-gift-of-imagination/">The GANfather: The man who’s given machines the gift of imagination</a>.</p> <p>This breakthrough stimulated the next spin of innovation and drug discovery entrepreneurship, including probably the most notable AI-driven company founded in the year 2014 -- <a target="_blank" href="https://www.biopharmatrend.com/m/company/insilico-medicine/">Insilico Medicine</a>. </p> <p>Co-founded by Dr. Alex Zhavoronkov, Insilico Medicine pioneered the application of deep learning for small molecule drug design and later -- target discovery. The company also incorporated GAN technology, and later built a number of GAN-based computational tools for drug discovery, including DruGAN for fingerprints, ORGAN for SMILEs, etc.</p> <p><img alt="" src="/static/img/ai_pipelines_img1_gans.c015f225dd1b.webp" /></p> <p>As per information I have received by email from Insilico Medicine, most of their targets are novel or have sufficient novelty aspect, and they managed to discover both novel targets and molecules for those targets relying mostly on their Pharma.AI engine (see Table 1 below for detailed pipeline information).</p> <p> </p> <h3>2015</h3> <p>This year, a prominent AI company XtalPi was founded on the MIT campus and in China, focusing from its inception on combining quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations.</p> <p>Interestingly, the company initially disclosed <a href="https://www.vbdata.cn/1518940518" rel="nofollow">an internal pipeline</a>, including at least 10 early stage discovery programs for a number of indications. However, at present, the company is focusing exclusively on partnerships and contract research services.</p> <p>As the a-1 filing documents indicate:</p> <p><em>“We have entered into a number of collaborations with biotechnology and pharmaceutical companies and academic institutions under which our collaborators pursue research in a number of therapeutic areas, such as oncology, neurology, respirology, and inflammatory diseases. In some cases, we retain at least partial ownership in the pipeline programs, typically in the double-digit percentage range, of the programs pursued under these collaborations. We are not responsible for advancing their pre-clinical development beyond generation of pre-clinical candidates.”</em></p> <p>As per company email for BiopharmaTrend, XtalPi never intended to pursue these projects in the same sense the other companies build up their pipelines. When they first launched their one-stop drug discovery business, the company started several proof-of-concept discovery projects in-house to showcase capabilities to clients and accumulate R&D data.</p> <p>Currently, XtalPi offers drug discovery solutions (both in small molecules and antibodies) that are powered by AI and (robotics) wet lab, which play a more prominent role in the zero-to-one innovation process of identifying novel molecules for clinical candidates.</p> <p> </p> <h3>2015-2019</h3> <p>Many notable AI-focused companies were founded in the coming years to tackle various aspects of drug discovery and development, including Insitro, Relay Therapeutics, Valo Health, Verge Genomics and others.  </p> <p>We should mention one notable exception -- New York-based AI drug discovery company <a target="_blank" href="https://www.biopharmatrend.com/m/company/schrodinger/">Schrödinger</a>, which was founded in 1990, well before the deep learning era. </p> <p>In the early years, the company was known as a well-established developer of cheminformatics solutions and software for drug research. Over the last decade, Schrödinger picked the AI trend as well and substantially augmented its product offering, launched novel AI-based tools, and created an internal drug candidate pipeline eventually, with two Phase 1 assets (Table 1). </p> <p>Trying to comprehend the market of AI in drug discovery and development,  it should be noted that a broad category of the 500+ AI startups recorded in <a target="_blank" href="https://www.biopharmatrend.com/our-products/ai-report/">BiopharmaTrend report</a> are not developing own drug candidates, they have no internal pipelines. </p> <p>For instance, many successful companies on the list, like <a target="_blank" href="https://www.biopharmatrend.com/m/company/cytoreason/">CytoReason</a> (AI-enabled disease modeling) or <a target="_blank" href="https://www.biopharmatrend.com/m/company/benchsci/">BenchSci</a> (AI-driven search engine for scientific reagents), contribute meaningfully to the advent of artificial intelligence in the pharma and biotech industries. But they focus on services, software licensing, and R&D partnerships. </p> <p>Two other broad categories of AI startups in the pharmaceutical industry include those in the drug repurposing space, like <a target="_blank" href="https://www.biopharmatrend.com/m/company/healx/">Healx</a> and <a target="_blank" href="https://www.biopharmatrend.com/m/company/lantern-pharma/">Lantern Pharma</a>, and AI vendors in the clinical trial space, like <a target="_blank" href="https://www.biopharmatrend.com/m/company/medidata-solutions/">Medidata</a>. </p> <p>In this report, we are exclusively focused on the companies that can design and advance drug candidates de novo (mostly, small molecules), and have internal pipelines. </p> <p> </p> <h2>A Wave of AI-designed Drug Candidates Hits The Breakwater</h2> <p>While hundreds of AI startups were founded since 2012, and raced towards building various systems for drug discovery, the wave of first preclinical and clinical candidates out of those efforts came later. </p> <p>For instance, Insilico made first headlines in 2019, having reached a notable proof-of-concept milestone where they predicted a molecule for a well-known target called DDR1 <a rel="nofollow" target="_blank" href="https://insilico.com/phase1#:~:text=In%202019%20we%20reached%20a,in%20vitro%20and%20in%20vivo.">in just 21 days</a> — and successfully validated prediction in vitro and in vivo. </p> <p>In the same year, Toronto-based <a target="_blank" href="https://www.biopharmatrend.com/m/company/deep-genomics/">Deep Genomics</a> announced “industry’s first AI-discovered therapeutic candidate” DG12P1, for Wilson disease. Deep Genomics’s AI platform pinpointed a specific genetic mutation and helped design a compound to correct it, all within 18 months.</p> <p> </p> <h3>2020-2022</h3> <p>Around 2020-2022, a series of preclinical candidate nominations included AI-discovered targets and molecules by BenevolentAI, Exscientia, Insilico Medicine, Deep Genomics, and others, and around 2022 several dozens of AI-generated molecules were in clinical trials. </p> <p>In order to comprehend the advance of multiple AI-discovered molecules over the years, we have conducted a historical pipeline analysis of some of the most developed AI in drug discovery platforms, including (alphabetically): </p> <p><a target="_blank" href="https://www.biopharmatrend.com/m/company/benevolentai/">BenevolentAI</a>, <a target="_blank" href="https://www.biopharmatrend.com/m/company/exscientia/">Exscientia</a>, <a target="_blank" href="https://www.biopharmatrend.com/m/company/insitro/">Insitro</a>, <a target="_blank" href="https://www.biopharmatrend.com/m/company/insilico-medicine/">Insilico Medicine</a>, <a target="_blank" href="https://www.biopharmatrend.com/m/company/recursion-pharmaceuticals/">Recursion Pharmaceuticals</a>, <a target="_blank" href="https://www.biopharmatrend.com/m/company/relay-therapeutics/">Relay Therapeutics</a>, <a target="_blank" href="https://www.biopharmatrend.com/m/company/schrodinger/">Schrödinger</a>, <a target="_blank" href="https://www.biopharmatrend.com/m/company/verge-genomics/">Verge Genomics</a>, and <a target="_blank" href="https://www.biopharmatrend.com/m/company/valo-health/">Valo Health</a>. </p> <p>We did not include partner programs in this analysis. </p> <p><a target="_blank" href="https://www.biopharmatrend.com/about/disclaimer/">Disclaimer</a> </p> </section> <div class="table-container"> <table id="pipelines-table" class=""> <thead> <tr> <td colspan="12" style="text-align: left;padding: 0 0 1em;"> <big><em>Table 1</em></big>    <button type="button" onclick="this.parentElement.parentElement.parentElement.parentElement.classList.toggle('pipelines-collapse')" class="switcher"> </button> <p style="max-width: 50em">DISCLAIMER: Historical data sourced from archived public sources, including Webarchive service (see references 1-25), the data is NOT provided by the companies, and may have evolved.</p> </td> </tr> <tr> <th style="width: 4em"><span style="color: transparent">———</span></th> <th style="width: 9em">Program</th> <th class="col-collapse">Ownership</th> <th class="col-collapse">Target</th> <th class="col-collapse">Indication</th> <th class="col-year">2019</th> <th class="col-year">2020</th> <th class="col-year">2021</th> <th class="col-year">2022</th> <th class="col-year">2023</th> </tr> </thead> <tbody> <tr class="divide-top"> <td class="company-cell" rowspan="20"><p><a href="/m/company/benevolentai/">BenevolentAI</a></p></td> <td>BEN-8744</td> <td class="col-collapse">Whole</td> <td class="col-collapse">PDE10</td> <td class="col-collapse">Ulcerative Colitis</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>BEN-28010</td> <td class="col-collapse">Whole</td> <td class="col-collapse">CHK1</td> <td class="col-collapse">Glioblastoma Multiforme</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>BEN-34712</td> <td class="col-collapse">Whole</td> <td class="col-collapse">RAR⍺β</td> <td class="col-collapse">ALS</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Parkinson's disease</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Fibrosis</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>Partnered Program</td> <td class="col-collapse">Co-owner w/ AstraZeneca</td> <td class="col-collapse">-</td> <td class="col-collapse">Chronic Kidney Disease</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ AstraZeneca</td> <td class="col-collapse">-</td> <td class="col-collapse">Idiopathic Pulmonary Fibrosis</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Merck</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Merck</td> <td class="col-collapse">-</td> <td class="col-collapse">Neurology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Merck</td> <td class="col-collapse">-</td> <td class="col-collapse">Immunology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>BEN-2293</td> <td class="col-collapse">Whole</td> <td class="col-collapse">TrkA, TrkB, and TrkC</td> <td class="col-collapse">Atopic Dermatitis</td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase2">Phase 2</span></td> <td class="col-year"><span class="pip pip-phase2 pip-failed">Phase 2`</span></td> </tr> <tr class=""> <td>BEN-9160</td> <td class="col-collapse">Whole</td> <td class="col-collapse">Bcr-Abl</td> <td class="col-collapse">ALS</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Inflammatory bowl disease (IBD)</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Antiviral</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">NASH</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Parkinson's disease</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Inflammation</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class="divide-top"> <td class="company-cell" rowspan="21"><p><a href="/m/company/exscientia/">Exscientia</a></p></td> <td>EXS21546</td> <td class="col-collapse">Majority, w/ Evotec</td> <td class="col-collapse">A2aR</td> <td class="col-collapse">High Adenosine Signature Cancers</td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase2">Phase 1/2</span></td> <td class="col-year"><span class="pip pip-phase2 pip-failed">Phase 1/2`</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">HPK1</td> <td class="col-collapse">Immuno-Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>EXS74539</td> <td class="col-collapse">Whole</td> <td class="col-collapse">LSD1</td> <td class="col-collapse">Oncology, AML, SCLC</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>EXS73565</td> <td class="col-collapse">Whole</td> <td class="col-collapse">MALT1</td> <td class="col-collapse">Oncology, Hematology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">Mpro</td> <td class="col-collapse">COVID-19</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Anti-infective</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">NLRP3</td> <td class="col-collapse">Inflammation and Immunity</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>GTAEXS617</td> <td class="col-collapse">Co-owner w/ Apeiron</td> <td class="col-collapse">CDK7</td> <td class="col-collapse">Transcriptionally addicted cancers</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase2">Phase 1/2</span></td> </tr> <tr class=""> <td>EXS4318</td> <td class="col-collapse">Out-licensed, BMS</td> <td class="col-collapse">PKC-theta</td> <td class="col-collapse">inflammatory and immunologic diseases</td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner</td> <td class="col-collapse">ENPP1</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner</td> <td class="col-collapse">ENPP1</td> <td class="col-collapse">HPP</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner</td> <td class="col-collapse">-</td> <td class="col-collapse">Inframmation and immunity</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner</td> <td class="col-collapse">-</td> <td class="col-collapse">Inflammation and Immunity</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner</td> <td class="col-collapse">-</td> <td class="col-collapse">Psychiatry</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class="divide-top"> <td class="company-cell" rowspan="21"><p><a href="/m/company/insilico-medicine/">Insilico Medicine</a></p></td> <td>INS018_055</td> <td class="col-collapse">Whole</td> <td class="col-collapse">TNIK</td> <td class="col-collapse">IPF</td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase2">Phase 2</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">TNIK</td> <td class="col-collapse">Kidney fibrosis</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">-</td> <td class="col-collapse">TNIK</td> <td class="col-collapse">Skin Fibrosis</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">TNIK</td> <td class="col-collapse">IPF (inhalable)</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>ISM012</td> <td class="col-collapse">Whole</td> <td class="col-collapse">PHD1/2</td> <td class="col-collapse">Anemia of Chronic Kedney Disease</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">PHD1/2</td> <td class="col-collapse">Infammatory bowl disease (IBD)</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>ISM8207</td> <td class="col-collapse">Co-owner w/ Fosun</td> <td class="col-collapse">QPCTL</td> <td class="col-collapse">Immuno-oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Fosun</td> <td class="col-collapse">-</td> <td class="col-collapse">Diabetic neuphropathy, FSGS</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>ISM3312</td> <td class="col-collapse">-</td> <td class="col-collapse">3CLpro</td> <td class="col-collapse">COVID-19</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>ISM3412</td> <td class="col-collapse">Whole</td> <td class="col-collapse">MAT2A</td> <td class="col-collapse">MTAP-/-cancer</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>ISM9274</td> <td class="col-collapse">Whole</td> <td class="col-collapse">CDK12/13</td> <td class="col-collapse">Solid tumors</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>ISM027</td> <td class="col-collapse">Whole</td> <td class="col-collapse">cMYC</td> <td class="col-collapse">Solid tumors</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>ISM022</td> <td class="col-collapse">Whole</td> <td class="col-collapse">CDK8</td> <td class="col-collapse">AML, Solid tumors</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>ISM023</td> <td class="col-collapse">Whole</td> <td class="col-collapse">PARP7</td> <td class="col-collapse">Solid tumors</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>ISM3091</td> <td class="col-collapse">Out-licensed, Exelixis</td> <td class="col-collapse">USP1</td> <td class="col-collapse">BRCA-mutant cancer</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>ISM5939</td> <td class="col-collapse">Whole</td> <td class="col-collapse">ENPP1</td> <td class="col-collapse">solid tumors</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>ISM5043</td> <td class="col-collapse">Out-licensed, Menarini</td> <td class="col-collapse">KAT6</td> <td class="col-collapse">ER+/HER2-breast cancer</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>ISM4525</td> <td class="col-collapse">Whole</td> <td class="col-collapse">DGKA</td> <td class="col-collapse">Solid tumors</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>ISM8001</td> <td class="col-collapse">Whole</td> <td class="col-collapse">FGFR2/3</td> <td class="col-collapse">Solid tumors</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>ISM016</td> <td class="col-collapse">Whole</td> <td class="col-collapse">NLRP3</td> <td class="col-collapse">Gout flare</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>ISM6331</td> <td class="col-collapse">Whole</td> <td class="col-collapse">TEAD</td> <td class="col-collapse">Solid tumors</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class="divide-top"> <td class="company-cell" rowspan="19"><p><a href="/m/company/recursion-pharmaceuticals/">Recursion Pharmaceuticals</a></p></td> <td>REC-4881</td> <td class="col-collapse">Whole</td> <td class="col-collapse">MEK1 and MEK2</td> <td class="col-collapse">Familial Adenomatous Polyposis</td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase2">Phase 2</span></td> </tr> <tr class=""> <td>REC-3599</td> <td class="col-collapse">Whole</td> <td class="col-collapse">PKC and GSK3ß</td> <td class="col-collapse">GM2 Gangliosidosis</td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase2 pip-failed">terminated</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>REC-2282</td> <td class="col-collapse">Whole</td> <td class="col-collapse">HDAC</td> <td class="col-collapse">Neurofibromatosis Type 2</td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase3">Phase 3</span></td> </tr> <tr class=""> <td>REC-994</td> <td class="col-collapse">Whole</td> <td class="col-collapse">antioxidant, no specific target</td> <td class="col-collapse">Cerebral Cavemous Malformation</td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase2">Phase 2</span></td> </tr> <tr class=""> <td>REC-3964</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Clostridium Difficile Colitis</td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Neuroinflammation</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Batten Disease</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Charcot-Marie-Tooth Disease Type 2</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Immune Checkpoint resistance in STK11-NSCLC</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncoloty</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>25 programs</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Various</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>REC-4881</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">AXIN1 or APC Mutant Cancers</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Pulmonary Arterial Hypertension</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>Immunotherapy Target Alpha</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>Immunotherapy Target Beta</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Hepatocellular Carcinoma</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">RBM39</td> <td class="col-collapse">HR-proficient Ovarian Cancer RBM39</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>Immunotherapy Target Delta</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class="divide-top"> <td class="company-cell" rowspan="11"><p><a href="/m/company/relay-therapeutics/">Relay Therapeutics</a></p></td> <td>RLY-4008</td> <td class="col-collapse">Whole</td> <td class="col-collapse">FGFR2 (mutant+WT)</td> <td class="col-collapse">FGFR2-altered cholangiocarcinoma (CCA)</td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase2">Phase 1/2</span></td> </tr> <tr class=""> <td>RLV-PI3K1047 (RLY-5836)</td> <td class="col-collapse">Whole</td> <td class="col-collapse">PI3Kα</td> <td class="col-collapse">-</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>RLY2608</td> <td class="col-collapse">Whole</td> <td class="col-collapse">PI3Kα</td> <td class="col-collapse">solid tumors with a PI3Kα mutation</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">PI3Kα</td> <td class="col-collapse">-</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>RLY-2139</td> <td class="col-collapse">Whole</td> <td class="col-collapse">CDK2</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">ERα</td> <td class="col-collapse">-</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>GDC-1971</td> <td class="col-collapse">Co-owner w/ Genentech</td> <td class="col-collapse">SHP2</td> <td class="col-collapse">Cancers, expand into multiple combination</td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Genetic disease</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Genetic disease</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class="divide-top"> <td class="company-cell" rowspan="38"><p><a href="/m/company/schrodinger/">Schrödinger</a></p></td> <td>SDGR3 (SGR-1505)</td> <td class="col-collapse">Whole</td> <td class="col-collapse">MALT1</td> <td class="col-collapse">Relapsed or refractory B-cell lymphoma, chronic lymphocytic leukemia</td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>SDGR1</td> <td class="col-collapse">Whole</td> <td class="col-collapse">CDC7</td> <td class="col-collapse">Esophagial and Lung Cancers,</td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>SGR-2921</td> <td class="col-collapse">Whole</td> <td class="col-collapse">CDC7</td> <td class="col-collapse">Hematological cancers and solid tumors</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>SDGR2</td> <td class="col-collapse">Whole</td> <td class="col-collapse">WEE1</td> <td class="col-collapse">Ovarian, Pancreatic, Breast and Lung Cancers</td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>SGR-3515</td> <td class="col-collapse">Whole</td> <td class="col-collapse">WEE1/MYT1</td> <td class="col-collapse">Solid tumors</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>SDGR4</td> <td class="col-collapse">Co-owner w/ BMS</td> <td class="col-collapse">HIF-2a</td> <td class="col-collapse">Renal Cell Carcinoma</td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>SDGR5</td> <td class="col-collapse">Co-owner w/ BMS</td> <td class="col-collapse">SOS1</td> <td class="col-collapse">KRAS-driven Cancers</td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ BMS</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology, Immunology, Neurology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ BMS</td> <td class="col-collapse">-</td> <td class="col-collapse">Neurology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ BMS</td> <td class="col-collapse">-</td> <td class="col-collapse">immunology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">LRRK2</td> <td class="col-collapse">Neurology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">PRMT5-MTA</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">EFGR(C797S)</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">NLRP3</td> <td class="col-collapse">Immunology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Immunology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ BMS</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ BMS</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ BMS</td> <td class="col-collapse">-</td> <td class="col-collapse">Immunology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ BMS</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology, Immunology, Neurology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Takeda</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Takeda</td> <td class="col-collapse">TYK2</td> <td class="col-collapse">Psoriasis</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-phase2">Phase 2</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Zai Lab</td> <td class="col-collapse">-</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Lilly</td> <td class="col-collapse">-</td> <td class="col-collapse">Immunology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Ajax</td> <td class="col-collapse">JAK2</td> <td class="col-collapse">Oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Bright Angel Therapeutics</td> <td class="col-collapse">HSP90</td> <td class="col-collapse">Antifungal</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ loxo Therapeutics</td> <td class="col-collapse">undisclosed</td> <td class="col-collapse">oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Morphic Therapeutic</td> <td class="col-collapse">α4β7</td> <td class="col-collapse">IBD</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-phase2">Phase 2</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Morphic Therapeutic</td> <td class="col-collapse">α4β7</td> <td class="col-collapse">GI indications</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Morphic Therapeutic</td> <td class="col-collapse">αvβ8</td> <td class="col-collapse">Solid tumors, fibrosis</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Morphic Therapeutic</td> <td class="col-collapse">-</td> <td class="col-collapse">Pulmonary arterial hypertension</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ NimbusTherapeutic</td> <td class="col-collapse">HPK1</td> <td class="col-collapse">Immuno-oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-phase2">Phase 1/2</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Otsuka</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Sanofi</td> <td class="col-collapse">-</td> <td class="col-collapse">oncology</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Structure Therapeutics</td> <td class="col-collapse">APJR</td> <td class="col-collapse">Pulmonary arterial hypertension</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Structure Therapeutics</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Structure Therapeutics</td> <td class="col-collapse">LPA1R</td> <td class="col-collapse">Idiopathic pulmonary fibrosis</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> </tr> <! -- XtalPi asked to remove this section --> <tr class="divide-top"> <td class="company-cell" rowspan="3"><p><a href="/m/company/insitro/">Insitro</a></p></td> <td>-</td> <td class="col-collapse">Co-owner w/ BMS, TSC alliance</td> <td class="col-collapse">-</td> <td class="col-collapse">Genetic Epilepsies, ALS</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Solid Tumors</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">MASLD, Obesity</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class="divide-top"> <td class="company-cell" rowspan="17"><p><a href="/m/company/verge-genomics/">Verge Genomics</a></p></td> <td>VRG50635</td> <td class="col-collapse">Whole</td> <td class="col-collapse">PIKfyve</td> <td class="col-collapse">ALS</td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase2">Phase 1/2</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Parkinson's Disease</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Parkinson's Disease</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Parkinson's Disease</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Frontotemporal Dementia</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Progressive Supranuclear Palsy</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Schizophrenia</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Neurodegenerative Diseases</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">-</td> <td class="col-collapse">Undisclosed</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Whole</td> <td class="col-collapse">PIKfyve</td> <td class="col-collapse">COVID-19</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Psoriasis</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Atopic Dermititis</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Crohn's Disease</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Ulcerative Colitis</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>Partnered Programs</td> <td class="col-collapse">Co-owner w/ Lilly</td> <td class="col-collapse">-</td> <td class="col-collapse">ALS</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Alexion</td> <td class="col-collapse">-</td> <td class="col-collapse">Neurodegenerative Diseases</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class=""> <td>-</td> <td class="col-collapse">Co-owner w/ Alexion</td> <td class="col-collapse">-</td> <td class="col-collapse">Neuromuscular Diseases</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> </tr> <tr class="divide-top"> <td class="company-cell" rowspan="17"><p><a href="/m/company/valo-health/">Valo Health</a></p></td> <td>OPL-0301</td> <td class="col-collapse">-</td> <td class="col-collapse">S1P1 agonist</td> <td class="col-collapse">Heart failure and Acute Kidney Injury</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase2">Phase 2</span></td> <td class="col-year"><span class="pip pip-phase2">Phase 2</span></td> </tr> <tr class=""> <td>OPL-0401</td> <td class="col-collapse">-</td> <td class="col-collapse">ROCK 1/2 inhibitor</td> <td class="col-collapse">Diabetic Retinopathy</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-phase1">Phase 1</span></td> <td class="col-year"><span class="pip pip-phase2">Phase 2</span></td> <td class="col-year"><span class="pip pip-phase2">Phase 2</span></td> </tr> <tr class=""> <td>OPAL-0022</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Atherosclerosis</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>OPAL-0004</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Atherosclerosis, Giloblastoma</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>OPAL-0018</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Atherosclerosis</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>OPAL-0003</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Heart Failure, Giloblastoma</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>OPL-0101</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Immuno-Oncology</td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-preclinical">Preclinical</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>OPAL-0021</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">cancer</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>OPAL-0015</td> <td class="col-collapse">-</td> <td class="col-collapse">USP28</td> <td class="col-collapse">NSCLC, Squamous Cell Carcinoma, Targeted Defined Tumors</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>OPAL-0024</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Solid Tumors</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>OPAL-0001</td> <td class="col-collapse">-</td> <td class="col-collapse">PARP1</td> <td class="col-collapse">Medula/Glioblastoma Brain Tumors, Breast Cancer</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>OPAL-0014</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Pancreatic Ductal Adenocarcinoma (PDAC), Targeted Defined Tumors</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>OPAL-0023</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Defined Tumors, Immune Modulation</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>OPAL-0012</td> <td class="col-collapse">-</td> <td class="col-collapse">USP7</td> <td class="col-collapse">NSCLC</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>OPAL-0016</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Induced Neuropathy and Cardiomyopathy</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>OPAL-0002</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Neurodegenerative disorders</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> <tr class=""> <td>OPAL-0006</td> <td class="col-collapse">-</td> <td class="col-collapse">-</td> <td class="col-collapse">Neurodegenerative: Oncology (metastatic)</td> <td class="col-year"> </td> <td class="col-year"> </td> <td class="col-year"><span class="pip pip-discovery">Discovery</span></td> <td class="col-year"><span class="pip pip-hold">unknown</span></td> <td class="col-year"> </td> </tr> </tbody> </table> </div> <div> <a target="_blank" href="/static/img/ai_pipelines_elipse_fullsize.293e22ae71ff.webp"> <img src="/static/img/ai_pipelines_elipse_fullsize.293e22ae71ff.webp"> </a> </div> <section class="well"> <h3>2023-present moment</h3> <p>In 2023, the first wave of AI-designed (or claimed so) drug candidates hit the breakwater. The industry recorded <a rel="nofollow" target="_blank" href="https://medcitynews.com/2023/12/ai-generated-drug-candidates-are-here-but-clinical-trial-wins-need-more-time/">a number of clinical trial setbacks</a> for some AI-designed drug candidates, including Exscientia's cancer drug candidate EXS21546 which was discontinued out of strategic pipeline prioritisation, as the company representatives explained in an email to BiopharmaTrend.</p> <p>An AI-inspired schizophrenia drug candidate from partners Sumitomo Pharma and Otsuka Pharmaceutical failed to outperform a placebo in two Phase 3 studies. Sunovion, a subsidiary of Sumitomo Pharma, brought compounds to the alliance that were then screened using PsychoGenics’s SmartCube technology, which employs computer vision to analyze and define behaviors of mice treated with a potential drug.</p> <p>Adding to negative statistics, BenevolentAI's lead drug BEN-2293 failed to beat a placebo in a Phase 2a atopic dermatitis study, leading to cutting up to 180 jobs and reorganizing its pipeline to conserve cash. The company’s valuation dropped significantly in 2022, has not recovered ever since, and is currently around $145 million (Table 2), a fraction of what it used to be in earlier years.  </p> <p>Notwithstanding years in business and hundreds of millions in raised capital, some AI companies have not produced any clinical drug candidates yet. </p> <p>For instance, according to a recent <a rel="nofollow" target="_blank" href="https://endpts.com/atomwise-ceo-on-ai-in-biotech-shifting-focus-to-tyk2-drug-and-pipeline/">Endpoints News </a>interview with Dr. Abraham Heifets, Co-founder and CEO of Atomwise -- the AI in drug discovery pioneer founded in 2012 and raised over $170 million, the company had to cut ‘hundreds of AI discovery programs‘ and focus on just several assets for internal development recently. Currently, all its drug candidates are in preclinical stage. </p> <p>Founded in 2018, and led by a prominent deep learning scientist Dr. Daphne Koller, Insitro is another example of a company with a seemingly “relaxed” pace of advancing its internal drug candidates. After 6 years in the business, and $643 million of venture capital money raised, the company only has 3 drug candidates in the discovery stage (Table 1). </p> <p>That being said, Insitro has a strong portfolio of external deals with BMS, Gilead and others, and the company is heavily focused on modeling disease biology. So the limited internal pipeline can be explained by a different focus, and probably we may expect rapid portfolio expansion in the near time.  </p> <p>On the other hand, the industry recorded distinct success stories with growing “AI-inspired” pipelines, like the one of <a target="_blank" href="https://www.biopharmatrend.com/m/company/insilico-medicine/">Insilico Medicine</a>, which managed to build an impressive clinical pipeline of 17 preclinical candidates in under 3 years. Several of those are now in clinical trials, including a recent phase 2 candidate for idiopathic pulmonary fibrosis (IPF), five phase 1 candidates for various indications, including kidney fibrosis, inflammatory bowel disease (IBD), immuno-oncology, and COVID-19, and around a dozen preclinical programs in late stages of development. </p> <p>It is noteworthy that the majority of Insilico Medicine’s AI-discovered programs are first-in-class drug candidates for high-novelty targets or best-in-class candidates for moderately novel targets. The company’s apparent ability to come up with novel targets consistently stems from its target discovery engine PandaOmics. </p> <p>Another leading player, <a target="_blank" href="https://www.biopharmatrend.com/m/company/recursion-pharmaceuticals/">Recursion Pharmaceuticals</a> seems to be progressing consistently, overall, as the company embraced a robust multifaceted approach to building its end-to-end AI engine Operation System, and its high throughput biology experimentation facilities and robotized lines. </p> <p>The company has a strong pipeline of two Phase 1 and three Phase 2 candidates, two of which were in-licensed from previous developers. One more candidate <a rel="nofollow" target="_blank" href="https://www.fiercebiotech.com/biotech/recursion-reprioritizes-dumping-rare-disease-asset-while-raking-150m">did not progress beyond Phase 1</a> and was put on hold.</p> <p>  It should be noted, however, that according to the Endpoints article, Recursion Pharmaceuticals <a rel="nofollow" target="_blank" href="https://endpts.com/first-ai-designed-drugs-fall-short-in-the-clinic-following-years-of-hype/">have not delivered on the promise of ‘generating 100 drugs‘ using AI</a>, as the company advertised a decade ago. It is illustrative of how challenging the drug discovery is, even with the cutting-edge AI technologies and R&D infrastructure. </p> <p>In 2023 <a target="_blank" href="https://www.biopharmatrend.com/m/company/verge-genomics/">Verge Genomics</a> got positive safety and tolerability data from the Phase 1 clinical trial for its leading candidate VRG50635, a potential best-in-class therapeutic for all forms of ALS. Verge Genomics used CONVERGE™, the company’s all-in-human, AI-powered platform to develop its drug discovery program.</p> <p>Also, the FDA's clearance of <a target="_blank" href="https://www.biopharmatrend.com/m/company/a2a-pharmaceuticals/">A2A Pharmaceuticals</a>'s Investigational New Drug (IND) application for A2A-252, a TACC3 protein-protein interaction (PPI) inhibitor, showcases the potential of AI in accelerating drug development. </p> <p>Utilizing its AI-driven SCULPT computational platform, A2A Pharmaceuticals, with a lean team of four and limited funding, managed to advance two clinical stage programs, including A2A-252.</p> <p> </p> <h2>AI in Drug Discovery Sector Keeps Consolidating</h2> <p>The AI in the drug discovery and development race has been going for more than a decade now, and today we see all signs of the sector’s consolidation. </p> <p>Over the last 6 years, there were more than 30 merger and acquisition events in this space. According to the <a target="_blank" href="https://www.biopharmatrend.com/our-products/ai-report/">BiopharmaTrend report</a> some of the AI-focused deals in drug discovery, biotech, and clinical trials space included: the 2018 acquisition of Flatiron Health by Roche for $1.9 billion; the 2019 acquisition of Numerate by Valo Health; the 2020 acquisition of Haystack Biosciences by Insitro; the 2021 acquisition of Prescient Design by Genentech; the 2022 acquisitions of Zymergen by Ginkgo Bioworks for $300 million; the 2023 acquisition of InstaDeep by BioNtech for $549 million and double acquisition of Cyclica and Valence Labs by Recursion Pharmaceuticals for around $90 million combined -- to name just a few. </p> <p>Some of the notable deals are summarized in the figure below:</p> <p><img alt="AI in Drug Discovery Sector Consolidation" src="/static/img/ai_pipelines_img2_acquisitions.1b8e5f9c23ff.webp" /><br> </p> <p>Another driver of consolidation is expansion of “big tech” giants into the life sciences, including NVIDIA, Alphabet, Microsoft and others. They leverage their cutting edge resources in artificial intelligence research, world-class tech infrastructures (software, cloud, computational power) and flexible business models. </p> <p>Famous <a rel="nofollow" target="_blank" href="https://www.newscientist.com/article/2330866-deepminds-protein-folding-ai-cracks-biologys-biggest-problem/">successes</a> of Alphabet subsidiary DeepMind in protein modeling space, Isomorphic Labs’ recent partnerships with Eli Lilly and Novartis, the advent of NVIDIA’s AI-based Clara Discovery platform for everything from drug design to healthcare research, and Microsoft Cloud for life sciences.</p> <p>As Dr. Alex Zhavoronkov writes in his <a rel="nofollow" target="_blank" href="https://www.forbes.com/sites/alexzhavoronkov/2024/01/08/five-ai-powered-drug-discovery-aidd-industry-predictions-for-2024/?sh=7950aa493f3c">Forbes article</a>: “In 2024, I predict NVIDIA will come out big with its healthcare platform so that the need for new AI in drug discovery (AIDD) companies will go away. Drug discovery players will be able to use NVIDIA tools in their cloud, on Amazon, or on massive clusters of NVIDIA GPUs locally. </p> <p>It is unlikely to hurt established AIDD players with end-to-end AIDD platforms and significant validation, but it will inhibit the formation of startups with little or now differentiation, and it will add more credibility to the field.”  </p> <p>Dr. Zhavoronkov continues about Microsoft: “In 2024, we should expect to see massive growth in LLMs in pharma and biotech, with Microsoft being the main provider. Even when some LLM startups achieve superior performance in benchmarks and come up with new models, they do not stand a chance in big pharma. </p> <p>Pharma is very conservative - there are too many compliance and legal challenges to deploying generative AI from a new vendor. Microsoft made it easy to use the latest OpenAI models on Azure Cloud and to implement sophisticated AI platform architectures. And Microsoft works all over the world. I predict many internal-external LLM architectures will be built on the Microsoft platform”.</p> <p>Next, according to the <a target="_blank" href="https://www.biopharmatrend.com/our-products/ai-report/">BiopharmaTrend report</a>, venture capital firms are increasingly prioritizing smaller numbers of established AI in drug discovery players over new platform companies, which is a sign of consolidation. </p> <p>Finally, ‘big pharma’ and leading biotech corporations are increasingly shifting from external partnerships towards <a rel="nofollow" target="_blank" href="https://www.bloomberg.com/news/articles/2024-01-31/ai-speeds-up-drug-development-but-effectiveness-is-untested">building their own AI muscle</a>, effectively diminishing opportunities for novel startups to win R&D dollars.</p> <p>Big pharma is increasingly choosing well established technology vendors and validated AI for drug discovery engines. </p> <p>The consolidation of the AI in the drug discovery sector naturally led to formation of a distinct group of AI frontrunners -- companies that managed to build sufficient AI capabilities, robust business models, and win major clients. From the Table 2 below one can see that several companies, including Insilico Medicine, Recursion Pharmaceuticals, Schodinger, and XtalPi demonstrate strong financials, compared to some of the peers in this space: </p> <p><a target="_blank" href="https://www.biopharmatrend.com/about/disclaimer/">Disclaimer</a></p> </section> <div><em>Table 2 **</em></div> <div class="table-container"> <table id="finance-table"> <thead> <tr> <th style="min-width: 10em"> </th> <th colspan="3">BenevolentAI ***</th> <th colspan="3">Exscientia ***</th> <th colspan="3">Insilico</th> <th colspan="3">Recursion Pharmaceuticals</th> <th colspan="3">Relay Therapeutics</th> <th colspan="3">Schrodinger</th> <th colspan="3">XtalPi **`</th> </tr> </thead> <tbody> <tr> <td>Year</td> <td>2021</td> <td>2022</td> <td>2023</td> <td>2021</td> <td>2022</td> <td>2023</td> <td>2021</td> <td>2022</td> <td>2023</td> <td>2021</td> <td>2022</td> <td>2023</td> <td>2021</td> <td>2022</td> <td>2023</td> <td>2021</td> <td>2022</td> <td>2023</td> <td>2021</td> <td>2022</td> <td>2023Q2</td> </tr> <tr> <td><b>Total Revenue</b></td> <td>6,254</td> <td>12,774</td> <td>9,334</td> <td>36,995</td> <td>32,932</td> <td>25,565</td> <td>4,713</td> <td>30,147</td> <td>51,180</td> <td>10,178</td> <td>39,843</td> <td>44,575</td> <td>3,029</td> <td>1,381</td> <td>25,546</td> <td>137,931</td> <td>180,955</td> <td>216,666</td> <td>9,878</td> <td>19,336</td> <td>11,299</td> </tr> <tr> <td><i>Drug discovery services</i></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td>3,687</td> <td>28,648</td> <td>47,818</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td>24,695</td> <td>45,377</td> <td>57,542</td> <td>6,189</td> <td>12,712</td> <td>5,100</td> </tr> <tr> <td><i>Software solution services</i></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td>1,026</td> <td>1,499</td> <td>3,362</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td>113,236</td> <td>135,578</td> <td>159,124</td> <td>3,689</td> <td>6,625</td> <td>6,199</td> </tr> <tr> <td><b>Total Revenue Growth, %</b></td> <td> </td> <td>104%</td> <td>-27%</td> <td> </td> <td>-11%</td> <td>-22%</td> <td> </td> <td>540%</td> <td>70%</td> <td> </td> <td>291%</td> <td>12%</td> <td> </td> <td>-54%</td> <td>1750%</td> <td> </td> <td>31%</td> <td>20%</td> <td> </td> <td>112%</td> <td> </td> </tr> <tr> <td><i>Drug discovery services Growth, %</i></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td>677%</td> <td>67%</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td>84%</td> <td>27%</td> <td> </td> <td>123%</td> <td> </td> </tr> <tr> <td><i>Software solution services Growth, %</i></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td>46%</td> <td>124%</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td>20%</td> <td>17%</td> <td> </td> <td>95%</td> <td> </td> </tr> <tr> <td><b>Research and development expenses</b></td> <td>-76,962</td> <td>-86,958</td> <td>-77,380</td> <td>-59,560</td> <td>-155,888</td> <td>-163,535</td> <td>-38,489</td> <td>-78,175</td> <td>-97,341</td> <td>-135,271</td> <td>-155,696</td> <td>-241,226</td> <td>-172,650</td> <td>-246,355</td> <td>-330,018</td> <td>-90,904</td> <td>-126,372</td> <td>-181,766</td> <td>-33,442</td> <td>-52,048</td> <td>-33,124</td> </tr> <tr> <td><b>Operating Loss</b></td> <td>-164,052</td> <td>-238,352</td> <td>-98,766</td> <td>-74,230</td> <td>-175,759</td> <td>-224,088</td> <td>-49,359</td> <td>-83,616</td> <td> </td> <td>-182,775</td> <td>-245,727</td> <td>-350,060</td> <td>-364,698</td> <td>-299,275</td> <td>-373,000</td> <td>-111,443</td> <td>-146,817</td> <td>-177,448</td> <td>-47,101</td> <td>-76,171</td> <td>-61,464</td> </tr> <tr> <td><b>Total current assets</b></td> <td>76,567</td> <td>183,977</td> <td>116,355</td> <td>786,694</td> <td>670,204</td> <td>515,567</td> <td>161,541</td> <td>218,751</td> <td>188,653</td> <td>534,718</td> <td>569,814</td> <td>438,137</td> <td>976,242</td> <td>1,019,505</td> <td>770,103</td> <td>625,060</td> <td>533,989</td> <td>567,796</td> <td>616,547</td> <td>521,516</td> <td>456,362</td> </tr> <tr class="divide-top"> <td>IPO Date</td> <td colspan="3">2021/12</td> <td colspan="3">2021/9</td> <td colspan="3"> </td> <td colspan="3">2021/4</td> <td colspan="3">2020/7</td> <td colspan="3">2020/2</td> <td colspan="3"> </td> </tr> <tr> <td>Post-money valuation of last financing round</td> <td colspan="3"> </td> <td colspan="3"> </td> <td colspan="3">894.7M</td> <td colspan="3"> </td> <td colspan="3"> </td> <td colspan="3"> </td> <td colspan="3">1,968M</td> </tr> <tr> <td>Valuation (As of Mar 26th 2024)</td> <td colspan="3">93M</td> <td colspan="3">749M</td> <td colspan="3"> </td> <td colspan="3">2,422M</td> <td colspan="3">993M</td> <td colspan="3">1,845M</td> <td colspan="3"> </td> </tr> <tr> <td>Biological ability</td> <td colspan="3">Partnerships</td> <td colspan="3">Partnerships</td> <td colspan="3">External user base</td> <td colspan="3">Partnerships</td> <td colspan="3"> </td> <td colspan="3"> </td> <td colspan="3"> </td> </tr> <tr> <td>Chemistry ability</td> <td colspan="3">Partnerships</td> <td colspan="3">Partnerships</td> <td colspan="3">External user base</td> <td colspan="3"> </td> <td colspan="3">Partnerships</td> <td colspan="3">External user base</td> <td colspan="3">External user base</td> </tr> <tr> <td>Clinical ability</td> <td colspan="3"> </td> <td colspan="3"> </td> <td colspan="3">External user base</td> <td colspan="3"> </td> <td colspan="3"> </td> <td colspan="3"> </td> <td colspan="3"> </td> </tr> <tr> <td>Therapeutic Area</td> <td colspan="3"> </td> <td colspan="3"> </td> <td colspan="3"> </td> <td colspan="3">Rare & Other, Oncology</td> <td colspan="3">Targeted Oncology, Genetic Disease</td> <td colspan="3"> </td> <td colspan="3"> </td> </tr> <tr> <td>Phase II</td> <td colspan="3">0</td> <td colspan="3">1</td> <td colspan="3">1</td> <td colspan="3">3</td> <td colspan="3">1</td> <td colspan="3">0</td> <td colspan="3">0</td> </tr> <tr> <td>Phase I</td> <td colspan="3">1</td> <td colspan="3">0</td> <td colspan="3">5</td> <td colspan="3">2</td> <td colspan="3">2</td> <td colspan="3">2</td> <td colspan="3">0</td> </tr> <tr> <td>IND enabling</td> <td colspan="3">2</td> <td colspan="3">2</td> <td colspan="3">9</td> <td colspan="3">2</td> <td colspan="3">1</td> <td colspan="3">2</td> <td colspan="3">3</td> </tr> </tbody> </table> <p>** - the data taken from annual reports, see references 26-40</p> <p style="max-width: 50em">*** - for comparison reasons, values in the UK companies reports (originally in GBP) have been converted to USD at the GBP/USD rate (closing price) as of 31 December of the year depending on the report: <br>2021 - 1.3522; 2022 - 1.2097; 2023 - 1.2732</p> <p style="max-width: 50em">**` - for comparison reasons, values in the XtalPi report (originally in RMB) have been converted to USD at the RMB/USD rate (closing price) as of 31 December of the year depending on the report: <br>2021 - 0.1573; 2022 - 0.145; 2023 - 0.1413</p> </div> <div><em>Table 3 ``</em></div> <div class="table-container"> <table id="finance-summary"> <thead> <tr> <th>Company</th> <th>Short % of Shares</th> <th>Current Price (USD) <br>2024-03-26 <br>(US Trading Hour)</th> <th>52-Week Price Change %</th> <th>Current MarketCap (USD'MM)</th> <th style="width: 12em;">Last 12 months' <br>Operating Cash Flow (USD'MM)</th> <th>Last 12 months' <br>Revenue (USD'MM)</th> <th>3 year's Revenue Trend</th> </tr> </thead> <tbody> <tr> <td>Recursion Pharmaceuticals, Inc</td> <td>18.25% <div class="chart-bar bar-yellow" style="width: 100%"></div> </td> <td>10.32</td> <td><span class="price-change-up">64.02%</span></td> <td>2,422 <div class="chart-bar bar-blue" style="width: 100%"></div> </td> <td>-287.8 <div class="chart-bar bar-red" style="width: 10.63em"></div> </td> <td>43.88 <div class="chart-bar bar-green" style="width: 1.62em"></div> </td> <td> <svg height="31" width="100" xmlns="http://www.w3.org/2000/svg"> <polyline points="0,30 50,9.7 100,6.8" style="fill:none;stroke:grey;stroke-width:2" /> </svg> </td> </tr> <tr> <td>Schrodinger, Inc.</td> <td>7.48% <div class="chart-bar bar-yellow" style="width: 41%"></div> </td> <td>25.65</td> <td><span class="price-change-up">5.07%</span></td> <td>1,845 <div class="chart-bar bar-blue" style="width: 76%"></div> </td> <td>-136.7 <div class="chart-bar bar-red" style="width: 5.05em"></div> </td> <td>216.67 <div class="chart-bar bar-green" style="width: 8em"></div> </td> <td> <svg height="31" width="100" xmlns="http://www.w3.org/2000/svg"> <polyline points="0,30 50,24 100,19.1" style="fill:none;stroke:grey;stroke-width:2" /> </svg> </td> </tr> <tr> <td>Relay Therapeutics, Inc.</td> <td>10.79% <div class="chart-bar bar-yellow" style="width: 59%"></div> </td> <td>7.57</td> <td><span class="price-change-down">-49.80%</span></td> <td>993 <div class="chart-bar bar-blue" style="width: 41%"></div> </td> <td>-300.3 <div class="chart-bar bar-red" style="width: 11.09em"></div> </td> <td>25.55 <div class="chart-bar bar-green" style="width: 0.94em"></div> </td> <td> <svg height="31" width="100" xmlns="http://www.w3.org/2000/svg"> <polyline points="0,28.1 50,30 100,1.6" style="fill:none;stroke:grey;stroke-width:2" /> </svg> </td> </tr> <tr> <td>Exscientia plc</td> <td>5.42% <div class="chart-bar bar-yellow" style="width: 30%"></div> </td> <td>5.74</td> <td><span class="price-change-up">9.19%</span></td> <td>749 <div class="chart-bar bar-blue" style="width: 31%"></div> </td> <td>-149.9 <div class="chart-bar bar-red" style="width: 5.53em"></div> </td> <td>25.5 <div class="chart-bar bar-green" style="width: 0.94em"></div> </td> <td> <svg height="31" width="100" xmlns="http://www.w3.org/2000/svg"> <polyline points="0,22 50,22.2 100,30" style="fill:none;stroke:grey;stroke-width:2" /> </svg> </td> </tr> <tr> <td>BenevolentAI</td> <td>N/A</td> <td>0.73</td> <td><span class="price-change-down">-70.25%</span></td> <td>93 <div class="chart-bar bar-blue" style="width: 4%"></div> </td> <td>-72.5 <div class="chart-bar bar-red" style="width: 2.68em"></div> </td> <td>9.27 <div class="chart-bar bar-green" style="width: 0.34em"></div> </td> <td> <svg height="31" width="100" xmlns="http://www.w3.org/2000/svg"> <polyline points="0,30 50,13.1 100,22.3" style="fill:none;stroke:grey;stroke-width:2" /> </svg> </td> </tr> <tr> <td>Insilico Medicine</td> <td>N/A</td> <td>N/A</td> <td>N/A</td> <td>895 <div class="chart-bar bar-blue" style="width: 37%"></div> </td> <td>-29.6 <div class="chart-bar bar-red" style="width: 1.09em"></div> </td> <td>51.18 <div class="chart-bar bar-green" style="width: 1.89em"></div> </td> <td> <svg height="31" width="100" xmlns="http://www.w3.org/2000/svg"> <polyline points="0,30 50,15.1 100,2.8" style="fill:none;stroke:grey;stroke-width:2" /> </svg> </td> </tr> </tbody> </table> <p> `` - data taken from Yahoo Finance for March 26, 2024. </p> </div> <section class="well"> <p>It is worth noting that XtalPi seems focused exclusively on the contract research business model. At least, the company removed its pipeline information from the english version of its website. </p>  <p> </p> <h2>Looking into the future</h2> <p>The AI in the drug discovery space is getting consolidated with the rising barriers of entry for new startups, but also more opportunities for those newcomers that do manage to innovate efficiently, raise money, and leverage novel technologies. </p> <p> </p> <h3>Big tech enters the game</h3> <p>A growing influence of large technology vendors, like Microsoft, Alphabet and NVIDIA can be expected, and they will be increasingly serving as gravitation points for novel startups. For instance, <a rel="nofollow" target="_blank" href="https://www.nvidia.com/en-us/industries/healthcare-life-sciences/">NVIDIA’s Inception program</a> already now nurtures over 1,800 healthcare startups developing cutting-edge, GPU-based tools to optimize operations, enhance diagnostics and develop novel therapeutics.</p> <p>In 2024, the pharmaceutical and biotechnology sectors are anticipated to significantly expand their adoption of large language models (LLMs), predominantly through Microsoft's Azure Cloud, leveraging OpenAI's models for AI-powered drug discovery (AIDD). Despite the emergence of startups with potentially superior LLMs, the stringent compliance and legal frameworks within the pharma industry favor established providers like Microsoft, which offers comprehensive support for deploying generative AI globally. The trend towards consolidation in the AIDD market is expected to intensify, with a few well-established entities dominating, thanks to their validated platforms and the industry's cautious approach towards adopting innovations from newer vendors.</p> <p> </p> <h3>Era of AI pilots with “big pharma” is over</h3> <p>Big pharma has grown AI muscle to the point that they can oftentimes innovate internally, and depend less on the external pilot programs. The era of numerous AI-deals with everyone around is over. In 2024 and beyond, we may expect an increasing amount of strategic partnerships between big pharma and the most established AI in drug discovery platforms.</p> <p>Such partnerships will be growing in scope and size of total remuneration. </p> <p>Already now some deals include not only promise of milestone future payments and royalty payments, but also sizable upfront payments. </p> <p>In September 2023, Insilico Medicine sold rights to develop and sell a potential cancer drug to California-based Exelixis Inc. for an upfront payment of $80 million and is co-developing another candidate for cancer with Shanghai Fosun Pharmaceutical Group Co., controlled by Chinese billionaire Guo Guangchang.</p> <p>Around the same time, Exscientia collaborated with Merck KGaA, focusing on AI-driven drug discovery in oncology, neuroinflammation, and immunology, with a $20 million upfront payment and potential milestones up to $674M plus royalties on sales for developed therapies.</p> <p> </p> <h3>AI validation in clinical trials</h3> <p>As more drug candidates from established AI in drug discovery players will be progressing along the clinical trial pipelines, we will have meaningful insights into how AI is really changing the quality of innovation. It is clear that AI can accelerate research and make it cheaper. But does it increase the probability of success? This is yet to be understood in more detail. </p> <p>At the same time, it is important to mention that while the role of AI in changing the paradigm of early drug discovery is still a matter of validation and more data, the role of AI in drug development is already felt. </p> <p>In a recent video<a rel="nofollow" target="_blank" href="https://www.youtube.com/watch?si=2ghZTPJDdpwdH_iG&v=1HXcU76gA7U&feature=youtu.be"> interview with CNBC</a>, Vas Narasimhan, CEO of Novartis, shares his vision about AI in drug discovery. He thinks it won’t impact early stages of drug discovery within the next five years (we do not quite share this opinion, based on our analysis of several leading companies, such as Insilico Medicine, Recursion Pharmaceuticals, and Schrodinger).</p> <p>However Vas points out that AI has already impacted drug development and clinical research: e.g.: new trial protocols, working with regulators, working with large patients datasets, etc.</p> <p>He estimates that AI already helps save 6-9 months of drug development, which can translate into notable financial savings and acceleration.</p> <p> </p> <h3>Data is new priority in the AI race</h3> <p>Finally, the leading AI companies have come to understand the critical importance of generating and possessing their own unique biological data. This realization marks a pivotal shift in the industry's approach to leveraging artificial intelligence for drug development.</p> <p>It is not enough any longer to have cutting-edge models and algorithms, no matter how sophisticated. It becomes a matter of strategic differentiation to be able to generate or otherwise acquire and control big datasets for model training (e.g. omics, imaging, EHR, etc). </p> <p>Some companies, like Moderna, Recursion Pharmaceuticals and XtalPi, naturally evolved as digital biotechs with AI-controlled robotized high throughput facilities for running preclinical experiments at scale. </p> <p>Insilico Medicine is a good example of an AI in drug discovery company that initially evolved as an algorithm-centric company with an efficient collaboration structure. But in the recent couple of years, the company focused massively on augmenting its capability with high throughput experimental capacity of its own, and in 2023, Insilico Medicine <a rel="nofollow" target="_blank" href="https://www.news-medical.net/news/20230105/Insilico-Medicine-launches-a-6th-generation-Intelligent-Robotics-Drug-Discovery-Laboratory.aspx">launched a 6th generation Intelligent robotics drug discovery laboratory</a>, located in Suzhou BioBAY Industrial Park, China.</p> <p>Exscientia is yet another example of this trend, as the company opened a facility in Oxfordshire, England, for AI and robotics integration in chemical synthesis and closed-loop drug design, aiming to minimize human intervention and accelerate experimental processes. </p> <p>Concurrently, the ethical use of AI gains prominence, with international efforts to establish guidelines following the<a rel="nofollow" target="_blank" href="https://www.europarl.europa.eu/topics/en/article/20230601STO93804/eu-ai-act-first-regulation-on-artificial-intelligence"> European Union directive</a> and a <a rel="nofollow" target="_blank" href="https://www.lawfaremedia.org/article/the-u.s.-plans-to-lead-the-way-on-global-ai-policy">US executive order</a>, addressing security risks and promoting responsible AI development in the wake of increasing accessibility to generative AI models.</p> <p> </p> <h3>Report methodology</h3> <p>The historical data analysis of therapeutic pipelines (Table 1) has been performed based on the available website snapshots from <a rel="nofollow" target="_blank" href="https://web.archive.org">Web Archive</a>, where we were able to analyze how pipeline diagrams looked in previous periods. In some cases, yearly financial reports were used to get pipeline information for previous years. </p> <p>The effort was made to track the progression of each molecule or program in any given pipeline over the years, and if the program was unavailable in the next year, it was generally assumed that the program was put on hold for various reasons. </p> <p>Financial data for Table 2 was obtained from relevant annual reports, in the case of publicly traded companies, and from other publicly available sources for private companies. </p> <p> </p> <h3>Correction policy</h3> <p>In our report on comparing 10 companies, including those that are publicly traded, we made every effort to ensure accuracy and transparency. </p> <p>Should any factual inaccuracies or outdated information be identified, we will promptly issue corrections in a dedicated section of our report. This correction policy applies to financial data, company profiles, and any comparative analysis presented. Stakeholders are encouraged to report potential inaccuracies to our editorial team via our official contact channels. Corrections will be clearly dated and described, maintaining the integrity of our comparative report and ensuring our readers have access to the most current and accurate information.</p> <p> </p> <h2>References</h2> <p>1. Schrodinger, pipeline, December 2023 <a rel="nofollow" target="_blank" href="https://www.schrodinger.com/pipeline">https://www.schrodinger.com/pipeline</a></p> <p>2. Schrodinger, pipeline, November 2022 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20221124124721/https://www.schrodinger.com/pipeline">https://web.archive.org/web/20221124124721/https://www.schrodinger.com/pipeline</a></p> <p>3. Schrodinger, pipeline, June 2021 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20210620183431/https://www.schrodinger.com/pipeline">https://web.archive.org/web/20210620183431/https://www.schrodinger.com/pipeline</a></p> <p>4. Schrodinger, pipeline, June 2020 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20200606152921/https://www.schrodinger.com/pipeline">https://web.archive.org/web/20200606152921/https://www.schrodinger.com/pipeline</a></p> <p>5. Schrodinger, pipeline, Juy 2019 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20190717045358/https://www.schrodinger.com/pipeline">https://web.archive.org/web/20190717045358/https://www.schrodinger.com/pipeline</a></p> <p>6. Recursion, pipeline, December 2023 <a rel="nofollow" target="_blank" href="https://www.recursion.com/pipeline">https://www.recursion.com/pipeline</a></p> <p>7. Recursion, pipeline, January 2022 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20220131104947/https://www.recursion.com/pipeline">https://web.archive.org/web/20220131104947/https://www.recursion.com/pipeline</a></p> <p>8. Recursion, pipeline, February 2021 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20210225041638/https://www.recursion.com/pipeline">https://web.archive.org/web/20210225041638/https://www.recursion.com/pipeline</a></p> <p>9. Recursion, pipeline, January 2021 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20210129043831/https://www.recursion.com/pipeline">https://web.archive.org/web/20210129043831/https://www.recursion.com/pipeline</a></p> <p>10. Exscientia, pipeline, November 2023 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20231130165922/https://www.exscientia.ai/pipeline">https://web.archive.org/web/20231130165922/https://www.exscientia.ai/pipeline</a></p> <p>11. Exscientia, PR, August 2022 <a rel="nofollow" target="_blank" href="https://www.businesswire.com/news/home/20220817005681/en/Exscientia-Business-Update-for-Second-Quarter-and-First-Half-2022">https://www.businesswire.com/news/home/20220817005681/en/Exscientia-Business-Update-for-Second-Quarter-and-First-Half-2022</a></p> <p>12. Exscientia, article, July 2022 <a rel="nofollow" target="_blank" href="https://www.nanalyze.com/2022/07/exscientia-stock-ai-drug-discovery/">https://www.nanalyze.com/2022/07/exscientia-stock-ai-drug-discovery/</a></p> <p>13. Exscientia, annual report, 2021 <a rel="nofollow" target="_blank" href="https://s28.q4cdn.com/460399462/files/doc_financials/2021/ar/2021-UK-Annual-Report.pdf">https://s28.q4cdn.com/460399462/files/doc_financials/2021/ar/2021-UK-Annual-Report.pdf</a></p> <p>14. Relay, pipeline, November 2023 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20231111223956/https://relaytx.com/pipeline/">https://web.archive.org/web/20231111223956/https://relaytx.com/pipeline/</a></p> <p>15. Relay, annual report (PDF), 2022 <a rel="nofollow" target="_blank" href="https://ir.relaytx.com/static-files/1b13dc48-4fb1-4ec3-b639-69636bc3ace1">https://ir.relaytx.com/static-files/1b13dc48-4fb1-4ec3-b639-69636bc3ace1</a></p> <p>16. Relay, annual report (PDF), 2021 <a rel="nofollow" target="_blank" href="https://ir.relaytx.com/static-files/65cffc5e-e6e3-42a3-9b87-cc44b93c2856">https://ir.relaytx.com/static-files/65cffc5e-e6e3-42a3-9b87-cc44b93c2856</a></p> <p>17. Relay, annual report (PDF), 2020 <a rel="nofollow" target="_blank" href="https://ir.relaytx.com/static-files/08d959ca-abd2-4a9c-bd25-be8eef73d732">https://ir.relaytx.com/static-files/08d959ca-abd2-4a9c-bd25-be8eef73d732</a></p> <p>18. BenevolentAI, pipeline, December 2023 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20231205114116/https://www.benevolent.com/pipeline/">https://web.archive.org/web/20231205114116/https://www.benevolent.com/pipeline/</a></p> <p>19. BenevolentAI, annual report (PDF), 2022 <a rel="nofollow" target="_blank" href="https://www.benevolent.com/application/files/9816/7939/1282/BenevolentAI_Annual_Report_2022.pdf">https://www.benevolent.com/application/files/9816/7939/1282/BenevolentAI_Annual_Report_2022.pdf</a></p> <p>20. Insilico, pipeline, December 2023 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20231204133620/https://insilico.com/pipeline">https://web.archive.org/web/20231204133620/https://insilico.com/pipeline</a></p> <p>21. Insilico, pipeline, October 2022 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20221007131323/https://insilico.com/pipeline">https://web.archive.org/web/20221007131323/https://insilico.com/pipeline</a></p> <p>22. Insilico, pipeline, February 2022 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20220213125657/https://insilico.com/pipeline">https://web.archive.org/web/20220213125657/https://insilico.com/pipeline</a></p>  <p>23. Verge Genomics, pipeline, February 2024 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20240306224636/https://www.vergegenomics.com/pipeline">https://web.archive.org/web/20240306224636/https://www.vergegenomics.com/pipeline</a></p> <p>24. Verge Genomics, pipeline, November 2022 <a rel="nofollow" target="_blank" href="https://web.archive.org/web/20221104085232/https://www.vergegenomics.com/pipeline">https://web.archive.org/web/20221104085232/https://www.vergegenomics.com/pipeline</a></p> <p>25. BenevolentAI, report release, 2021 and 2022 <a rel="nofollow" target="_blank" href="https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-unaudited-preliminary-results-year-ended-31-december-2022/">https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-unaudited-preliminary-results-year-ended-31-december-2022/</a></p> <p>26. BenevolentAI, report release, 2023 <a rel="nofollow" target="_blank" href="https://www.benevolent.com/application/files/2417/1136/4663/BenevolentAI_Annual_Report_2023.pdf">https://www.benevolent.com/application/files/2417/1136/4663/BenevolentAI_Annual_Report_2023.pdf</a></p> <p>27. Exscientia, annual report (PDF), 2022 <a rel="nofollow" target="_blank" href="https://s28.q4cdn.com/460399462/files/doc_financials/2022/ar/EXAI_FY22-AR_final_compressed.pdf">https://s28.q4cdn.com/460399462/files/doc_financials/2022/ar/EXAI_FY22-AR_final_compressed.pdf</a></p> <p>28. Exscientia, annual report (PDF), 2023 <a rel="nofollow" target="_blank" href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0001865408/2e2ce7ec-55dc-4fe6-afa6-d0437f22ada4.pdf">https://d18rn0p25nwr6d.cloudfront.net/CIK-0001865408/2e2ce7ec-55dc-4fe6-afa6-d0437f22ada4.pdf</a></p> <p>29. Recursion, annual report (HTML), 2021 <a rel="nofollow" target="_blank" href="https://ir.recursion.com/node/6926/html">https://ir.recursion.com/node/6926/html</a></p> <p>30. Recursion, annual report (HTML), 2022 <a rel="nofollow" target="_blank" href="https://ir.recursion.com/node/8131/html">https://ir.recursion.com/node/8131/html</a></p> <p>31. Recursion, annual report (HTML), 2023 <a rel="nofollow" target="_blank" href="https://ir.recursion.com/node/9691/html">https://ir.recursion.com/node/9691/html</a></p> <p>32. Relay, annual report (HTML), 2021 <a rel="nofollow" target="_blank" href="https://ir.relaytx.com/node/7691/html">https://ir.relaytx.com/node/7691/html</a></p> <p>33. Relay, annual report (HTML), 2022 <a rel="nofollow" target="_blank" href="https://ir.relaytx.com/node/8531/html">https://ir.relaytx.com/node/8531/html</a></p> <p>34. Relay, annual report (HTML), 2023 <a rel="nofollow" target="_blank" href="https://ir.relaytx.com/node/9196/html">https://ir.relaytx.com/node/9196/html</a></p> <p>35. Schrodinger, annual report (PDF), 2021 <a rel="nofollow" target="_blank" href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0001490978/7a72e457-9a9e-4efc-b9b3-5ead018c904d.pdf">https://d18rn0p25nwr6d.cloudfront.net/CIK-0001490978/7a72e457-9a9e-4efc-b9b3-5ead018c904d.pdf</a></p> <p>36. Schrodinger, annual report (PDF), 2022 <a rel="nofollow" target="_blank" href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0001490978/6835c32b-f977-482f-82c5-254066f66d06.pdf">https://d18rn0p25nwr6d.cloudfront.net/CIK-0001490978/6835c32b-f977-482f-82c5-254066f66d06.pdf</a></p> <p>37. Schrodinger, annual report (PDF), 2023 <a rel="nofollow" target="_blank" href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0001490978/b3224b2d-5cc5-4081-ba8b-d89a31181139.pdf">https://d18rn0p25nwr6d.cloudfront.net/CIK-0001490978/b3224b2d-5cc5-4081-ba8b-d89a31181139.pdf</a></p> <p>38. XtalPi, report, 2021, 2022, 2023Q2 <a rel="nofollow" target="_blank" href="https://www1.hkexnews.hk/app/sehk/2023/105964/documents/sehk23113001942.pdf">https://www1.hkexnews.hk/app/sehk/2023/105964/documents/sehk23113001942.pdf</a></p> <p>39. Insilico, annual report (PDF), 2023 <a rel="nofollow" target="_blank" href="https://www1.hkexnews.hk/app/sehk/2024/106323/documents/sehk24032702892.pdf">https://www1.hkexnews.hk/app/sehk/2024/106323/documents/sehk24032702892.pdf</a></p> </section> </article> <div class="platform-block"> <div class="container"> <div class="row"> <div class="col-lg-6 col-12"> <h3>About Us</h3> <p>We have been tracking the adoption of artificial intelligence in the pharmaceutical and biotech industries since 2016.</p> <p> Having accumulated extensive knowledge about this industry sector, we have become a reputable agency offering strategic consulting and market research services. </p> <br> </div> <div class="col-lg-6 col-12"> <h3>Questions or Suggestions?</h3> <form action="/a/contact/" class="api-form" method="post"> </form> </div> </div> </div> <div id="article-sign"> #BioPharmaTrend </div> </div> </div> <footer id="main-footer"><div class="container"> <div class="row"> <div class="col-12 col-sm-6 col-lg-3"> <h4 class="footer-logo"><span style="font-weight: 900">BiopharmaTrend</span>.com</h4> <div style="margin-bottom: 1.25em" class="footer-logo-slogan">Where Tech Meets Bio</div>  <div style="margin-bottom: 0.5em;"><a href="#main-footer" onclick="toggleMailingPopup(true)" style="color: lemonchiffon"> <img src="/static/img/sm-mail.a3210e82fe37.png" alt="mail" width="32" height="32" />  <b>Newsletter</b> </a></div> <div style="margin-bottom: 0.5em"><a href="https://www.linkedin.com/company/biopharmatrend-com/" rel="nofollow" target="_blank"> <img src="/static/img/sm-in.fb9ea368635d.png" alt="in" width="32" height="32" />  LinkedIn </a></div> <div style="margin-bottom: 0.5em"><a href="https://twitter.com/BiopharmaTrend" rel="nofollow" target="_blank"> <img src="/static/img/sm-x.9f3327271e1a.png" alt="x" width="32" height="32" />  X </a></div> <div style="margin-bottom: 0.5em"><a href="https://news.google.com/publications/CAAqBwgKMOaRugsw86zRAw?hl=en-US&gl=US&ceid=US:en" rel="nofollow" target="_blank"> <img src="/static/img/sm-gnews.ac9eb4674c84.png" alt="gnews" width="32" height="32" />  Google News </a></div> <div><a href="/rss/" rel="nofollow" target="_blank"> <img src="/static/img/sm-rss.bcd2cefd2eba.png" alt="rss" width="32" height="32" />  RSS Feed </a></div> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>About</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/about/">What we do</a></li> <li><a href="/editorial-calendar/">Editorial Calendar</a></li> <li><a href="/about/press-citations/">Citations and Press Coverage</a></li> <li><a href="/terms-of-use/">Terms of Use</a></li> <li><a href="/privacy-policy/">Privacy Policy</a></li>  <li><a href="/about/disclaimer/">Disclaimer</a></li> </ul> </nav> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>We Offer</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/premium-content/"><b style="color: lemonchiffon">Premium Content</b></a></li> <li><a href="/m/marketplace/">BioTech Scout</a></li> <li><a href="/our-products/">Reports</a></li> <li><a href="/section/interviews/">Interviews</a></li> <li><a href="/events/">Partner Events</a></li> <li><a href="/section/case-studies/">Case Studies</a></li> </ul> </nav> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>Opportunities</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/membership/">Membership</a></li> <li><a href="/advertising-media-kit/">Advertise</a></li> <li><a href="/m/editor-tool/">Submit Company</a></li> <li><a href="/contributor/">Write for Us</a></li> <li><a href="/guest-blog/guidelines/">Author Guidelines</a></li> <li><a href="/a/contact/">Contact Us</a></li> </ul> </nav> </div> </div> <hr> <div class="text-right">© BPT Analytics LTD 2024</div> </div></footer> <div id="bpt-consent"><div class="container"> <div class="row"> <div class="col-12 col-md-6 col-lg-8"> We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our <a href="/cookies-policy/">cookies policy</a>. </div> <div class="col-12 col-md-6 col-lg-4 text-right"> <button class="btn btn-primary btn-sm" type="button" onclick="changeConsent('analytics')" style="white-space:unset">Agree</button> </div> </div> </div></div> <div id="login-popup" class="hidden popup"> <div class="close" onclick="this.parentElement.classList.add('hidden')"><i class="glyphicon glyphicon-remove"></i></div> <div class="popup-content" style="width: 25em;"> <form method="post" class="api-form" action="/a/login/?next=/ai-drug-discovery-pipeline/"></form> </div> </div> <div id="subscription-popup" class="hidden popup"> <div class="close" onclick="this.parentElement.classList.add('hidden')"><i class="glyphicon glyphicon-remove"></i></div> <div id="subscription-popup-iframe" class="popup-content" style="width: 25em;"> </div> </div> <div id="scroll-top-pixel-anchor"></div> <button id="go-top" onclick="window.scrollTo({top: 20, left: 0, behavior: 'smooth'})">^</button> <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.3.1/jquery.min.js"></script> <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.4.1/js/bootstrap.min.js"></script> <script src="/static/js/main.df923d2272d3.js"></script> <script type="text/javascript"> if ( "IntersectionObserver" in window && "IntersectionObserverEntry" in window && "intersectionRatio" in window.IntersectionObserverEntry.prototype ) { let observer = new IntersectionObserver(entries => { if (entries[0].boundingClientRect.y < 0) { document.body.classList.add("scroll-top"); } else { document.body.classList.remove("scroll-top"); } }); observer.observe(document.getElementById("scroll-top-pixel-anchor")); } </script> </body> </html>

CINXE.COM

It’s Been a Decade of AI in the Drug Discovery Race. What’s Next?